探讨特布他林联合糖皮质激素治疗慢阻肺急性加重期的临床疗效

Exploration on the Clinical Effect of Terbutaline Combined with Glucocorticoid in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的分析特布他林联合糖皮质激素治疗慢阻肺急性加重期的临床疗效。方法纳入98例慢阻肺急性加重期患者,纳入时间在2019年3月—2020年3月,掷骰子后随机分为治疗组(特布他林联合糖皮质激素治疗,n=49)和普通组(特布他林治疗,n=49),观察两组血气指标、肺功能指标及临床疗效。结果治疗组患者治疗前PaO2水平为(7.74±1.36)kPa、PaCO2水平为(9.41±1.58)kPa,与普通组的(7.81±1.44)kPa、(9.43±1.66)kPa相比,差异无统计学意义(t=0.247、0.061,P=0.805、0.951)。治疗组患者治疗后PaO2水平(11.32±1.28)kPa高于普通组(8.94±1.53)kPa,PaCO2水平(6.78±1.15)kPa低于普通组(8.59±1.07)kPa,差异有统计学意义(t=8.352、8.066,P<0.001)。治疗组患者治疗前6MWT水平为(318.75±28.64)m、FEV1水平为(1.32±0.22)L、FVC水平为(2.31±0.47)L,与普通组(319.39±27.11)m、(1.34±0.19)L、(2.28±0.33)L相比,差异无统计学意义(t=0.114、0.482、0.366,P=0.910、0.631、0.715)。治疗组患者治疗后6MWT水平(431.29±32.53)m、FEV1水平(2.26±0.75)L、FVC水平(3.11±0.45)L高于普通组的(398.07±32.16)m、(1.51±0.68)L、(2.69±0.62)L,差异有统计学意义(t=5.084、5.186、3.838,P<0.05)。治疗组治疗有效率为93.88%,普通组治疗有效率为79.59%,治疗组治疗有效率93.88%更高,差异有统计学意义(χ^(2)=4.346,P=0.037)。结论对慢阻肺急性加重期患者行特布他林联合糖皮质激素治疗,能改善血气指标及肺功能,且治疗有效率较高,临床疗效显著。

Objective To analyze the clinical efficacy of terbutaline combined with glucocorticoid in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods 98 patients with acute exacerbation of chronic obstructive pulmonary disease were enrolled from March 2019 to March 2020.After rolling the dice,they were randomly divided into treatment group(terbutaline combined with glucocorticoid therapy,n=49)and normal group(terbutaline treatment,n=49),observed the blood gas indexes,lung function indexes and clinical efficacy of the two groups.Results The PaO2 level of the patients in the treatment group before treatment was(7.74±1.36)kPa,and the PaCO2 level was(9.41±1.58)kPa,which had no difference compared with(7.81±1.44)kPa and(9.43±1.66)kPa of the general group,the difference was statistically significant(t=0.247,0.061,P=0.805,0.951).After treatment,the PaO2 level(11.32±1.28)kPa of patients in the treatment group was higher than the normal group(8.94±1.53)kPa,and the PaCO2 level(6.78±1.15)kPa was lower than the normal group(8.59±1.07)kPa,the difference was statistically significant(t=8.352,8.066,P<0.001).Before treatment,the 6MWT level of patients in the treatment group was(318.75±28.64)m,the FEV1 level was(1.32±0.22)L,and the FVC level was(2.31±0.47)L,which was compared with the normal group(319.39±27.11)m and(1.34±0.19)L and(2.28±0.33)L,the difference was not statistically significant(t=0.114,0.482,0.366,P=0.910,0.631,0.715).After treatment,the 6MWT level(431.29±32.53)m,FEV1 level(2.26±0.75)L,and FVC level(3.11±0.45)L of patients in the treatment group were higher than those of the normal group(398.07±32.16)m,(1.51±0.68)L,(2.69±0.62)L,the difference was statistically significant(t=5.084,5.186,3.838,P<0.001).The treatment effective rate was 93.88%in the treatment group,79.59%in the normal group,and the treatment effective rate(93.88%)in the treatment group was higher,the difference was not statistically significant(χ^(2)=4.346,P=0.037).Conclusion Terbutaline combined with glucocorticoid treatment for patients with acute exacerbation of chronic obstructive pulmonary disease can improve blood gas indicators and lung function,and the treatment efficiency is high,and the clinical effect is significant.